Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes

PNEUMOVAX™ 23, a 23-valent polysaccharide pneumococcal vaccine (PPV23), covers 65% to 91% of the isolates recovered from adult cases of invasive pneumococcal disease. Several studies have demonstrated that pneumococcal serotypes 31, 11A, 35F, 17F, 3, 16F, 19F, 15B, and 10A are associated with higher...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Hum Vaccin Immunother
Главные авторы: Ciprero, Karen L., Marchese, Rocio D., Richard, Patrick, Baudin, Martine, Sterling, Tina M., Manoff, Susan B., Radley, David, Stek, Jon E., Soubeyrand, Benoît, Grabenstein, John D., Samson, Sandrine I., Musey, Luwy K.
Формат: Artigo
Язык:Inglês
Опубликовано: Taylor & Francis 2016
Предметы:
Research Papers
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4994760/
https://ncbi.nlm.nih.gov/pubmed/27002793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2016.1156270
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы